4-Sep-2026
Ionis drops as Novartis posts late-stage trial setback for heart disease drug
Seeking Alpha News (Fri, 4-Sep 5:00 PM ET)
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Business Wire (Thu, 3-Sep 7:30 AM ET)
Business Wire (Sun, 30-Aug 11:30 AM ET)
Business Wire (Mon, 24-Aug 7:30 AM ET)
Business Wire (Mon, 17-Aug 9:33 AM ET)
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Business Wire (Tue, 4-Aug 4:01 PM ET)
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Business Wire (Tue, 4-Aug 4:00 PM ET)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Mon, 3-Aug 4:30 PM ET)
Business Wire (Mon, 27-Jul 7:30 AM ET)
Market Chameleon (Wed, 22-Jul 7:07 AM ET)
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Arrowhead Pharmaceuticals trades on the NASDAQ stock market under the symbol ARWR.
As of September 4, 2026, ARWR stock price declined to $86.34 with 677,337 million shares trading.
ARWR has a beta of 1.64, meaning it tends to be more sensitive to market movements. ARWR has a correlation of 0.13 to the broad based SPY ETF.
ARWR has a market cap of $12.16 billion. This is considered a Large Cap stock.
Last quarter Arrowhead Pharmaceuticals reported $75 million in Revenue and -$1.36 earnings per share. This beat revenue expectation by $24 million and missed earnings estimates by -$.17.
In the last 3 years, ARWR traded as high as $95.49 and as low as $9.57.
The top ETF exchange traded funds that ARWR belongs to (by Net Assets): IJH, VTI, VB, XMMO, VBK.
ARWR has outperformed the market in the last year with a return of +208.4%, while the SPY ETF gained +19.8%. In the last 3 month period, ARWR beat the market returning +14.9%, while SPY returned +2.0%. However, in the most recent 2 weeks ARWR has underperformed the stock market by returning -0.9%, while SPY returned +0.6%.
ARWR support price is $84.56 and resistance is $88.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARWR shares will trade within this expected range on the day.
